ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Aflibercept Biosimilars Market Research Report 2025
Published Date: March 2025
|
Report Code: QYRE-Auto-14Q10125
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Aflibercept Biosimilars Market Research Report 2022
BUY CHAPTERS

Global Aflibercept Biosimilars Market Research Report 2025

Code: QYRE-Auto-14Q10125
Report
March 2025
Pages:68
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Biocon Ltd.
Regeneron Pharmaceuticals
Bayer HealthCare
Kanghong Pharma

The global market for Aflibercept Biosimilars was valued at US$ 9681 million in the year 2024 and is projected to reach a revised size of US$ 10660 million by 2031, growing at a CAGR of 1.4% during the forecast period.

Aflibercept Biosimilars Market

Aflibercept Biosimilars Market

Aflibercept (Eylea) is a recombinant fusion protein that contains Ig-like domain 2 of VEGFR1 and Ig-like domain 3 of VEGFR2. It forms a fusion protein with the Fc segment of human IgG1 and can bind to VEGF-A and VEGF. -B and PlGF are one of the classic representative drugs of "Xypre". Age-related macular degeneration (AMD) and diabetic macular edema (DME) are both important factors leading to vision loss in elderly patients. Aflibercept biosimilars are used to treat patients with wet age-related macular degeneration (DME). AMD), diabetic macular edema (DME) and diabetic retinopathy (DR), becoming the standard of care.
Global key players of Aflibercept Biosimilars include Regeneron Pharmaceuticals, Bayer HealthCare and Kanghong Pharma, etc. The top three players hold a share about 100%. North America is the largest market, has a share about 77%. In terms of product type, 2mg is the largest segment, occupied for a share of about 100%, and in terms of application, Hospitals has a share about 71 percent.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Aflibercept Biosimilars, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Aflibercept Biosimilars.
The Aflibercept Biosimilars market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Aflibercept Biosimilars market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Aflibercept Biosimilars manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Aflibercept Biosimilars Market Report

Report Metric Details
Report Name Aflibercept Biosimilars Market
Accounted market size in year US$ 9681 million
Forecasted market size in 2031 US$ 10660 million
CAGR 1.4%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
  • 2mg
  • 8mg
Segment by Application
  • Hospitals
  • Clinics
  • Others
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Regeneron Pharmaceuticals, Bayer HealthCare, Kanghong Pharma, Biocon
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Aflibercept Biosimilars manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Aflibercept Biosimilars in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

How fast is Aflibercept Biosimilars Market growing?

Ans: The Aflibercept Biosimilars Market witnessing a CAGR of 1.4% during the forecast period 2025-2031.

What is the Aflibercept Biosimilars Market size in 2031?

Ans: The Aflibercept Biosimilars Market size in 2031 will be US$ 10660 million.

What is the market share of major companies in Aflibercept Biosimilars Market?

Ans: The top three players hold a share about 100%.

What is the Aflibercept Biosimilars Market share by region?

Ans: North America is the largest market, has a share about 77%.

What is the Aflibercept Biosimilars Market share by type?

Ans: In terms of product type, 2mg is the largest segment, occupied for a share of about 100%, and in terms of application, Hospitals has a share about 71 percent.

Who are the main players in the Aflibercept Biosimilars Market report?

Ans: The main players in the Aflibercept Biosimilars Market are Regeneron Pharmaceuticals, Bayer HealthCare, Kanghong Pharma, Biocon

What are the Application segmentation covered in the Aflibercept Biosimilars Market report?

Ans: The Applications covered in the Aflibercept Biosimilars Market report are Hospitals, Clinics, Others

What are the Type segmentation covered in the Aflibercept Biosimilars Market report?

Ans: The Types covered in the Aflibercept Biosimilars Market report are 2mg, 8mg

Recommended Reports

Ophthalmic Therapies

Biosimilars Market

Retinal Disorders

1 Aflibercept Biosimilars Market Overview
1.1 Product Definition
1.2 Aflibercept Biosimilars by Type
1.2.1 Global Aflibercept Biosimilars Market Value Comparison by Type (2024 VS 2031)
1.2.2 2mg
1.2.3 8mg
1.3 Aflibercept Biosimilars by Application
1.3.1 Global Aflibercept Biosimilars Market Value by Application (2024 VS 2031)
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Global Aflibercept Biosimilars Market Size Estimates and Forecasts
1.4.1 Global Aflibercept Biosimilars Revenue 2020-2031
1.4.2 Global Aflibercept Biosimilars Sales 2020-2031
1.4.3 Global Aflibercept Biosimilars Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Aflibercept Biosimilars Market Competition by Manufacturers
2.1 Global Aflibercept Biosimilars Sales Market Share by Manufacturers (2020-2025)
2.2 Global Aflibercept Biosimilars Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Aflibercept Biosimilars Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Aflibercept Biosimilars, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Aflibercept Biosimilars, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Aflibercept Biosimilars, Product Type & Application
2.7 Global Key Manufacturers of Aflibercept Biosimilars, Date of Enter into This Industry
2.8 Global Aflibercept Biosimilars Market Competitive Situation and Trends
2.8.1 Global Aflibercept Biosimilars Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Aflibercept Biosimilars Players Market Share by Revenue
2.8.3 Global Aflibercept Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Aflibercept Biosimilars Market Scenario by Region
3.1 Global Aflibercept Biosimilars Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Aflibercept Biosimilars Sales by Region: 2020-2031
3.2.1 Global Aflibercept Biosimilars Sales by Region: 2020-2025
3.2.2 Global Aflibercept Biosimilars Sales by Region: 2026-2031
3.3 Global Aflibercept Biosimilars Revenue by Region: 2020-2031
3.3.1 Global Aflibercept Biosimilars Revenue by Region: 2020-2025
3.3.2 Global Aflibercept Biosimilars Revenue by Region: 2026-2031
3.4 North America Aflibercept Biosimilars Market Facts & Figures by Country
3.4.1 North America Aflibercept Biosimilars Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Aflibercept Biosimilars Sales by Country (2020-2031)
3.4.3 North America Aflibercept Biosimilars Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Aflibercept Biosimilars Market Facts & Figures by Country
3.5.1 Europe Aflibercept Biosimilars Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Aflibercept Biosimilars Sales by Country (2020-2031)
3.5.3 Europe Aflibercept Biosimilars Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Aflibercept Biosimilars Market Facts & Figures by Region
3.6.1 Asia Pacific Aflibercept Biosimilars Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Aflibercept Biosimilars Sales by Region (2020-2031)
3.6.3 Asia Pacific Aflibercept Biosimilars Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Aflibercept Biosimilars Market Facts & Figures by Country
3.7.1 Latin America Aflibercept Biosimilars Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Aflibercept Biosimilars Sales by Country (2020-2031)
3.7.3 Latin America Aflibercept Biosimilars Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Aflibercept Biosimilars Market Facts & Figures by Country
3.8.1 Middle East and Africa Aflibercept Biosimilars Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Aflibercept Biosimilars Sales by Country (2020-2031)
3.8.3 Middle East and Africa Aflibercept Biosimilars Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Aflibercept Biosimilars Sales by Type (2020-2031)
4.1.1 Global Aflibercept Biosimilars Sales by Type (2020-2025)
4.1.2 Global Aflibercept Biosimilars Sales by Type (2026-2031)
4.1.3 Global Aflibercept Biosimilars Sales Market Share by Type (2020-2031)
4.2 Global Aflibercept Biosimilars Revenue by Type (2020-2031)
4.2.1 Global Aflibercept Biosimilars Revenue by Type (2020-2025)
4.2.2 Global Aflibercept Biosimilars Revenue by Type (2026-2031)
4.2.3 Global Aflibercept Biosimilars Revenue Market Share by Type (2020-2031)
4.3 Global Aflibercept Biosimilars Price by Type (2020-2031)
5 Segment by Application
5.1 Global Aflibercept Biosimilars Sales by Application (2020-2031)
5.1.1 Global Aflibercept Biosimilars Sales by Application (2020-2025)
5.1.2 Global Aflibercept Biosimilars Sales by Application (2026-2031)
5.1.3 Global Aflibercept Biosimilars Sales Market Share by Application (2020-2031)
5.2 Global Aflibercept Biosimilars Revenue by Application (2020-2031)
5.2.1 Global Aflibercept Biosimilars Revenue by Application (2020-2025)
5.2.2 Global Aflibercept Biosimilars Revenue by Application (2026-2031)
5.2.3 Global Aflibercept Biosimilars Revenue Market Share by Application (2020-2031)
5.3 Global Aflibercept Biosimilars Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Regeneron Pharmaceuticals
6.1.1 Regeneron Pharmaceuticals Company Information
6.1.2 Regeneron Pharmaceuticals Description and Business Overview
6.1.3 Regeneron Pharmaceuticals Aflibercept Biosimilars Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Regeneron Pharmaceuticals Aflibercept Biosimilars Product Portfolio
6.1.5 Regeneron Pharmaceuticals Recent Developments/Updates
6.2 Bayer HealthCare
6.2.1 Bayer HealthCare Company Information
6.2.2 Bayer HealthCare Description and Business Overview
6.2.3 Bayer HealthCare Aflibercept Biosimilars Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Bayer HealthCare Aflibercept Biosimilars Product Portfolio
6.2.5 Bayer HealthCare Recent Developments/Updates
6.3 Kanghong Pharma
6.3.1 Kanghong Pharma Company Information
6.3.2 Kanghong Pharma Description and Business Overview
6.3.3 Kanghong Pharma Aflibercept Biosimilars Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Kanghong Pharma Aflibercept Biosimilars Product Portfolio
6.3.5 Kanghong Pharma Recent Developments/Updates
6.4 Biocon
6.4.1 Biocon Company Information
6.4.2 Biocon Description and Business Overview
6.4.3 Biocon Aflibercept Biosimilars Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Biocon Aflibercept Biosimilars Product Portfolio
6.4.5 Biocon Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Aflibercept Biosimilars Industry Chain Analysis
7.2 Aflibercept Biosimilars Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Aflibercept Biosimilars Production Mode & Process Analysis
7.4 Aflibercept Biosimilars Sales and Marketing
7.4.1 Aflibercept Biosimilars Sales Channels
7.4.2 Aflibercept Biosimilars Distributors
7.5 Aflibercept Biosimilars Customer Analysis
8 Aflibercept Biosimilars Market Dynamics
8.1 Aflibercept Biosimilars Industry Trends
8.2 Aflibercept Biosimilars Market Drivers
8.3 Aflibercept Biosimilars Market Challenges
8.4 Aflibercept Biosimilars Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Biocon Ltd.
Regeneron Pharmaceuticals
Bayer HealthCare
Kanghong Pharma
List of Tables
 Table 1. Global Aflibercept Biosimilars Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Aflibercept Biosimilars Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Aflibercept Biosimilars Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Aflibercept Biosimilars Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Aflibercept Biosimilars Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Aflibercept Biosimilars Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Aflibercept Biosimilars Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Aflibercept Biosimilars Average Price (US$/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Aflibercept Biosimilars, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Aflibercept Biosimilars, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Aflibercept Biosimilars, Product Type & Application
 Table 12. Global Key Manufacturers of Aflibercept Biosimilars, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Aflibercept Biosimilars by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Aflibercept Biosimilars as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Aflibercept Biosimilars Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Aflibercept Biosimilars Sales by Region (2020-2025) & (K Units)
 Table 18. Global Aflibercept Biosimilars Sales Market Share by Region (2020-2025)
 Table 19. Global Aflibercept Biosimilars Sales by Region (2026-2031) & (K Units)
 Table 20. Global Aflibercept Biosimilars Sales Market Share by Region (2026-2031)
 Table 21. Global Aflibercept Biosimilars Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Aflibercept Biosimilars Revenue Market Share by Region (2020-2025)
 Table 23. Global Aflibercept Biosimilars Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Aflibercept Biosimilars Revenue Market Share by Region (2026-2031)
 Table 25. North America Aflibercept Biosimilars Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Aflibercept Biosimilars Sales by Country (2020-2025) & (K Units)
 Table 27. North America Aflibercept Biosimilars Sales by Country (2026-2031) & (K Units)
 Table 28. North America Aflibercept Biosimilars Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Aflibercept Biosimilars Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Aflibercept Biosimilars Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Aflibercept Biosimilars Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Aflibercept Biosimilars Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Aflibercept Biosimilars Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Aflibercept Biosimilars Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Aflibercept Biosimilars Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Aflibercept Biosimilars Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Aflibercept Biosimilars Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Aflibercept Biosimilars Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Aflibercept Biosimilars Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Aflibercept Biosimilars Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Aflibercept Biosimilars Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Aflibercept Biosimilars Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Aflibercept Biosimilars Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Aflibercept Biosimilars Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Aflibercept Biosimilars Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Aflibercept Biosimilars Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Aflibercept Biosimilars Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Aflibercept Biosimilars Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Aflibercept Biosimilars Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Aflibercept Biosimilars Sales (K Units) by Type (2020-2025)
 Table 51. Global Aflibercept Biosimilars Sales (K Units) by Type (2026-2031)
 Table 52. Global Aflibercept Biosimilars Sales Market Share by Type (2020-2025)
 Table 53. Global Aflibercept Biosimilars Sales Market Share by Type (2026-2031)
 Table 54. Global Aflibercept Biosimilars Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Aflibercept Biosimilars Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Aflibercept Biosimilars Revenue Market Share by Type (2020-2025)
 Table 57. Global Aflibercept Biosimilars Revenue Market Share by Type (2026-2031)
 Table 58. Global Aflibercept Biosimilars Price (US$/Unit) by Type (2020-2025)
 Table 59. Global Aflibercept Biosimilars Price (US$/Unit) by Type (2026-2031)
 Table 60. Global Aflibercept Biosimilars Sales (K Units) by Application (2020-2025)
 Table 61. Global Aflibercept Biosimilars Sales (K Units) by Application (2026-2031)
 Table 62. Global Aflibercept Biosimilars Sales Market Share by Application (2020-2025)
 Table 63. Global Aflibercept Biosimilars Sales Market Share by Application (2026-2031)
 Table 64. Global Aflibercept Biosimilars Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Aflibercept Biosimilars Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Aflibercept Biosimilars Revenue Market Share by Application (2020-2025)
 Table 67. Global Aflibercept Biosimilars Revenue Market Share by Application (2026-2031)
 Table 68. Global Aflibercept Biosimilars Price (US$/Unit) by Application (2020-2025)
 Table 69. Global Aflibercept Biosimilars Price (US$/Unit) by Application (2026-2031)
 Table 70. Regeneron Pharmaceuticals Company Information
 Table 71. Regeneron Pharmaceuticals Description and Business Overview
 Table 72. Regeneron Pharmaceuticals Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 73. Regeneron Pharmaceuticals Aflibercept Biosimilars Product
 Table 74. Regeneron Pharmaceuticals Recent Developments/Updates
 Table 75. Bayer HealthCare Company Information
 Table 76. Bayer HealthCare Description and Business Overview
 Table 77. Bayer HealthCare Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 78. Bayer HealthCare Aflibercept Biosimilars Product
 Table 79. Bayer HealthCare Recent Developments/Updates
 Table 80. Kanghong Pharma Company Information
 Table 81. Kanghong Pharma Description and Business Overview
 Table 82. Kanghong Pharma Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 83. Kanghong Pharma Aflibercept Biosimilars Product
 Table 84. Kanghong Pharma Recent Developments/Updates
 Table 85. Biocon Company Information
 Table 86. Biocon Description and Business Overview
 Table 87. Biocon Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 88. Biocon Aflibercept Biosimilars Product
 Table 89. Biocon Recent Developments/Updates
 Table 90. Key Raw Materials Lists
 Table 91. Raw Materials Key Suppliers Lists
 Table 92. Aflibercept Biosimilars Distributors List
 Table 93. Aflibercept Biosimilars Customers List
 Table 94. Aflibercept Biosimilars Market Trends
 Table 95. Aflibercept Biosimilars Market Drivers
 Table 96. Aflibercept Biosimilars Market Challenges
 Table 97. Aflibercept Biosimilars Market Restraints
 Table 98. Research Programs/Design for This Report
 Table 99. Key Data Information from Secondary Sources
 Table 100. Key Data Information from Primary Sources
 Table 101. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Aflibercept Biosimilars
 Figure 2. Global Aflibercept Biosimilars Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Aflibercept Biosimilars Market Share by Type: 2024 & 2031
 Figure 4. 2mg Product Picture
 Figure 5. 8mg Product Picture
 Figure 6. Global Aflibercept Biosimilars Market Value by Application (2020-2031) & (US$ Million)
 Figure 7. Global Aflibercept Biosimilars Market Share by Application: 2024 & 2031
 Figure 8. Hospitals
 Figure 9. Clinics
 Figure 10. Others
 Figure 11. Global Aflibercept Biosimilars Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 12. Global Aflibercept Biosimilars Market Size (2020-2031) & (US$ Million)
 Figure 13. Global Aflibercept Biosimilars Sales (2020-2031) & (K Units)
 Figure 14. Global Aflibercept Biosimilars Average Price (US$/Unit) & (2020-2031)
 Figure 15. Aflibercept Biosimilars Report Years Considered
 Figure 16. Aflibercept Biosimilars Sales Share by Manufacturers in 2024
 Figure 17. Global Aflibercept Biosimilars Revenue Share by Manufacturers in 2024
 Figure 18. Global 5 and 10 Largest Aflibercept Biosimilars Players: Market Share by Revenue in Aflibercept Biosimilars in 2024
 Figure 19. Aflibercept Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 20. Global Aflibercept Biosimilars Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 21. North America Aflibercept Biosimilars Sales Market Share by Country (2020-2031)
 Figure 22. North America Aflibercept Biosimilars Revenue Market Share by Country (2020-2031)
 Figure 23. United States Aflibercept Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 24. Canada Aflibercept Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 25. Europe Aflibercept Biosimilars Sales Market Share by Country (2020-2031)
 Figure 26. Europe Aflibercept Biosimilars Revenue Market Share by Country (2020-2031)
 Figure 27. Germany Aflibercept Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 28. France Aflibercept Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. U.K. Aflibercept Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. Italy Aflibercept Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. Russia Aflibercept Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Asia Pacific Aflibercept Biosimilars Sales Market Share by Region (2020-2031)
 Figure 33. Asia Pacific Aflibercept Biosimilars Revenue Market Share by Region (2020-2031)
 Figure 34. China Aflibercept Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. Japan Aflibercept Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. South Korea Aflibercept Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. India Aflibercept Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. Australia Aflibercept Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. China Taiwan Aflibercept Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Southeast Asia Aflibercept Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Latin America Aflibercept Biosimilars Sales Market Share by Country (2020-2031)
 Figure 42. Latin America Aflibercept Biosimilars Revenue Market Share by Country (2020-2031)
 Figure 43. Mexico Aflibercept Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Brazil Aflibercept Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Argentina Aflibercept Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Middle East and Africa Aflibercept Biosimilars Sales Market Share by Country (2020-2031)
 Figure 47. Middle East and Africa Aflibercept Biosimilars Revenue Market Share by Country (2020-2031)
 Figure 48. Turkey Aflibercept Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. Saudi Arabia Aflibercept Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 50. UAE Aflibercept Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Global Sales Market Share of Aflibercept Biosimilars by Type (2020-2031)
 Figure 52. Global Revenue Market Share of Aflibercept Biosimilars by Type (2020-2031)
 Figure 53. Global Aflibercept Biosimilars Price (US$/Unit) by Type (2020-2031)
 Figure 54. Global Sales Market Share of Aflibercept Biosimilars by Application (2020-2031)
 Figure 55. Global Revenue Market Share of Aflibercept Biosimilars by Application (2020-2031)
 Figure 56. Global Aflibercept Biosimilars Price (US$/Unit) by Application (2020-2031)
 Figure 57. Aflibercept Biosimilars Value Chain
 Figure 58. Channels of Distribution (Direct Vs Distribution)
 Figure 59. Bottom-up and Top-down Approaches for This Report
 Figure 60. Data Triangulation
 Figure 61. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Accenture

SIMILAR REPORTS

Eylea Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Aflibercept Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Anti VEGF Drugs for the Treatment of Wet AMD Market Research Report 2024
Global Fusion Protein Eye Injections Market Research Report 2024
Global Fusion Protein Anti VEGF Ophthalmic Drugs Market Research Report 2024
Lucentis Ranibizumab and Biosimilar Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Conbercept Market Research Report 2024
Global Broluzumab Biosimilars Market Research Report 2025
Global Raibizumab Biosimilars Market Research Report 2025
Global Ranibizumab Drugs and Biosimilars Market Research Report 2024
Global Anti VEGF Ophthalmic Drugs Market Research Report 2024
Global Anti VEGT Drugs Market Research Report 2024
Global Monoclonal Antibody Anti VEGF Ophthalmic Drugs Market Research Report 2024
Global Age Related Macular Degeneration AMD Treatment Drugs Market Research Report 2024
Global VEGF A Inhibitor Market Research Report 2024
Global Macular Degeneration AMD and Other Retinal Diseases Market Research Report 2024
Global Anti VEGF Intravitreal Drugs Market Research Report 2024
Global Fusion Protein VEGF Inhibitor Market Research Report 2024
Global Ranibizumab Injection Market Research Report 2024
Global VEGFA Antibody Market Research Report 2024
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions